Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
2006 ◽
Vol 17
(4)
◽
pp. 401-409
◽
Keyword(s):
2005 ◽
Vol 23
(16_suppl)
◽
pp. 7035-7035
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 16
(17)
◽
pp. 7859-7863
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7580-7580
◽
Keyword(s):
2012 ◽
Vol 28
(8)
◽
pp. 1253-1262
◽
Keyword(s):